Black Diamond Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Black Diamond Therapeutics

08/11/2021 14:31

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a quarterly
adjusted loss of 97 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 98 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Black Diamond Therapeutics Inc's reported EPS for the quarter
was a loss of 97 cents​.
* The mean earnings estimate of analysts had fallen by
about 16.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Black Diamond Therapeutics Inc shares had fallen by 5.0% this
quarter and lost 74.9% so far this year.
* The company reported a quarterly loss of $35.08 million.
* Wall Street's median 12-month price target for Black Diamond
Therapeutics Inc is $33.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 8 at 02:31 p.m.
 ​All figures in US dollars unless otherwise stated